MTF Biologics introduces new putty-like cartilage allograft

MTF Biologics expanded its portfolio with the launch of CartiMax viable cartilage allograft. CartiMax is a putty-like cartilage allograft designed to easily fill lesions in the knee, foot and ankle. According to a company press release, the off-the shelf product demonstrates stable viability up to 1-year post-cryopreservation and offers the clinical benefits of a viable cartilage matrix with live cells.

MTF Biologics introduced CartiMax with its commercial partner ConMed during the American Academy of Orthopaedic Surgeons Annual Meeting.

“CartiMax is the result of years of development and collaboration between MTF Biologics and surgeons and partners across the nation,” Joe Yaccarino, president and CEO of MTF Biologics, said in the release. “Surgeons have not had many options to easily fill cartilage defects, and CartiMax will provide an ideal option that they’ve been looking for. Its texture and malleability allow it to fill a defect of varying shapes and sizes, and its 1-year shelf life offers a lot of flexibility. We are proud to bring this innovation to orthopedic surgeons and their patients.”

The putty-like design of the allograft allows surgeons to mold and fill up to a 5-cm lesion without the need for templates or anchors, according to the release. Benefits of the product include its ability to provide functioning, viable chondrocytes and an extracellular matrix that contains the necessary building blocks for cartilage repair. CartiMax has demonstrated stable viability up to 1-year post-cryopreservation. Additionally, the product reportedly requires less preparation and saves time due to its putty-like consistency that conforms to defects of different shapes and sizes. This mailability reportedly eliminates the need for measuring, templates, trimming, gluing or suturing.

Reference: